Today: 20 March 2026
Subscribe
Browse Category

NASDAQ:INTS 30 October 2025 - 31 October 2025

Tiny Biotech INTENSITY THERAPEUTICS Stock Skyrockets on Cancer Therapy Breakthrough – Experts See Big Upside

Biotech Bombshell: Intensity Therapeutics (INTS) Surges Nearly 400% on Major Cancer Trial News

Shares of Intensity Therapeutics closed at $1.32 on Oct. 30, surging nearly 395% intraday after Phase 1/2 trial data for INT230-6 showed a 75% disease-control rate in metastatic cancer. Over a billion shares traded, dwarfing the usual volume. After-hours, the price fell to around $0.90. The company’s market cap remains under $65 million.
31 October 2025
··
Tiny Biotech INTENSITY THERAPEUTICS Stock Skyrockets on Cancer Therapy Breakthrough – Experts See Big Upside

Tiny Biotech INTENSITY THERAPEUTICS Stock Skyrockets on Cancer Therapy Breakthrough – Experts See Big Upside

Intensity Therapeutics shares surged nearly 200% on Oct. 30, 2025, after Phase 1/2 trial results for INT230-6 showed a 75% disease control rate and median survival of 11.9 months in advanced cancer patients. The stock traded around $0.27 with a market cap near $13.1 million and daily volume spiking to 279 million shares. INT230-6 is in late-stage trials for sarcoma and breast cancer.
30 October 2025
·
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 30.10.2025

US stocks fell Oct. 30, with the S&P 500 down 0.99% and Nasdaq off 1.57%. Oracle shares dropped 6.8% to $256.28 despite analysts raising price targets and maintaining buy ratings. Liberty Latin America slid about 6% in a month, closing near $7.77, well below its $10.63 fair value estimate. Intensity Therapeutics surged nearly 400%, while CERO plunged almost 95%.
30 October 2025
·······

Stock Market Today

  • Tenaz Energy Soars 16.2% on C$316 Million Profit and Production Surge
    March 20, 2026, 1:39 PM EDT. Tenaz Energy Corp (TSX:TNZ) posted a remarkable turnaround in 2025 with a net income of C$315.61 million, reversing a loss from the previous year. The company's production climbed to 9,609 barrels of oil equivalent per day (boe/d), driving a 16.2% jump in its share price. Tenaz also completed a buyback of 336,000 shares worth C$6.13 million, signaling strong capital discipline. Despite these gains, risks persist including high interest costs on C$140 million in notes and dependence on acquisitions. Market analysts display a wide range of fair value estimates, reflecting varied outlooks. Investors should carefully weigh these factors as Tenaz shifts from a speculative play to a scaled, cash-generating oil and gas producer.
Go toTop